Romoli M, Mazzocchetti P, D’Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C (2019) Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol 17(10):926–946. https://doi.org/10.2174/1570159x17666181227165722
Article CAS PubMed PubMed Central Google Scholar
Global, regional, and national burden of neurological disorders (2019) 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18 (5): 459–480. https://doi.org/10.1016/s1474-4422(18)30499-x
Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, Scheibe F, Jan S (2015) The economic impact of epilepsy: a systematic review. BMC Neurol 15(1):245. https://doi.org/10.1186/s12883-015-0494-y
Article PubMed PubMed Central Google Scholar
Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, Perucca P (2018) Epilepsy. Nature Reviews Disease Primers 4. https://doi.org/10.1038/nrdp.2018.24
Guo J, Ma J, Wang S, Li X, Ji H, Li Y, Peng F, Sun Y (2022) Valproic acid after neurosurgery induces elevated risk of liver injury: a prospective nested case-control study. Ann Pharmacother 56(8):888–897. https://doi.org/10.1177/10600280211055508
Article CAS PubMed Google Scholar
Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 37(12):1160–1167. https://doi.org/10.1002/j.1552-4604.1997.tb04301.x
Article CAS PubMed Google Scholar
Blanco-Serrano B, Otero M, Santos-Buelga D, García-Sánchez M, Serrano J, Domínguez-Gil A (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20(5):233–240
Article CAS PubMed Google Scholar
Yukawa E, Nonaka T, Yukawa M, Higuchi S, Kuroda T, Goto Y (2003) Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther 28(6):497–504
Article CAS PubMed Google Scholar
Vučićević K, Miljković B, Pokrajac M, Prostran M, Martinović Ž, Grabnar I (2009) The influence of drug–drug interaction and patients’ characteristics on valproic acid’s clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci 38(5):512–518
Jankovic S, Milovanovic J, Jankovic S (2010) Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther 48(11):767
Article CAS PubMed Google Scholar
Ibarra M, Vázquez M, Fagiolino P, Derendorf H (2013) Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 40:479–486
Article CAS PubMed Google Scholar
Lin W-w, Jiao Z, Wang C-l, Wang H-y, Ma C-l, Huang P-f, Guo X-z, Liu Y-w (2015) Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit 37(1):76–83
Methaneethorn J (2017) Population pharmacokinetics of valproic acid in patients with mania: implication for individualized dosing regimens. Clin Ther 39(6):1171–1181. https://doi.org/10.1016/j.clinthera.2017.04.005
Article CAS PubMed Google Scholar
Alqahtani S, Alandas N, Alsultan A (2019) Estimation of apparent clearance of valproic acid in adult Saudi patients. Int j clin pharm-net 41(4):1056–1061
Teixeira-da-Silva P, Pérez-Blanco JS, Santos-Buelga D, Otero MJ, García MJ (2022) Population pharmacokinetics of valproic acid in pediatric and adult Caucasian patients. Pharmaceutics 14(4):811. https://doi.org/10.3390/pharmaceutics14040811
Zang YN, Guo W, Niu MX, Bao S, Wang Q, Wang Y, Dong F, Li AN, Ruan CJ (2022) Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder. Eur J Clin Pharmacol 78(3):405–418. https://doi.org/10.1007/s00228-021-03246-2
Article CAS PubMed Google Scholar
Methaneethorn J (2018) A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol 84(5):816–834. https://doi.org/10.1111/bcp.13510
Article PubMed PubMed Central Google Scholar
El Desoky ES, Fuseau E, EL Din Amry S, Cosson V (2004) Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 59:783–790
Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T (2014) Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE 9(11):e111066
Article PubMed PubMed Central Google Scholar
Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE (2007) Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 29(5):571–575
Article CAS PubMed Google Scholar
Zang Y-N, Guo W, Dong F, Li A-N, de Leon J, Ruan C-J (2022) Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. Expert Rev Clin Pharmacol 15(5):621–635. https://doi.org/10.1080/17512433.2022.2075849
Article CAS PubMed Google Scholar
TANIKAWA K, MATSUMOTO Y, MATSUMOTO M, FUKUOKA M, YAMAMOTO R, ENDO K, SAWACHI T, NAKAMURA T (1998) Population pharmacokinetic parameters of valproic acid; conventional and slow release formulation. Rinsho yakuri/Jpn J Clin Pharmacol Ther 29(3):489–94
Jankovic S, Milovanovic J (2007) Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol 29(10):673–680
Article CAS PubMed Google Scholar
Methaneethorn J, Lohitnavy M (2020) External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients. Eur J Hosp Pharm 27(3):168–172. https://doi.org/10.1136/ejhpharm-2018-001653
Yang L, Yang N, Yi B, Pei Q, Huang Z (2022) Population pharmacokinetic evaluation with external validation of tacrolimus in Chinese primary nephrotic syndrome patients. Pharm Res 39(8):1907–1920. https://doi.org/10.1007/s11095-022-03273-3
Article CAS PubMed Google Scholar
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143–151. https://doi.org/10.1208/s12248-011-9255-z
Article PubMed PubMed Central Google Scholar
Comets E, Brendel K, Mentré F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154–166
Gumbert SD, Kork F, Jackson ML, Vanga N, Ghebremichael SJ, Wang CY, Eltzschig HK (2020) Perioperative acute kidney injury. Anesthesiology 132(1):180–204. https://doi.org/10.1097/ALN.0000000000002968
De Vlieger G, Meyfroidt G (2023) Kidney dysfunction after traumatic brain injury: pathophysiology and general management. Neurocrit Care 38(2):504–516. https://doi.org/10.1007/s12028-022-01630-z
Patsalos PN (2022) Valproic Acid. In: Patsalos PN (ed) Antiseizure Medication Interactions: A Clinical Guideed. Springer International Publishing, pp 261–267
Correa T, Rodriguez I, Romano S (2008) Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 29(9):511–520. https://doi.org/10.1002/bdd.636
Article CAS PubMed Google Scholar
Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagaswa K (2014) Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE 9(11):e111066. https://doi.org/10.1371/journal.pone.0111066
留言 (0)